12 reports

  • DRUG DEVELOPMENT THROUGH COLLABORATION

Acceleron Pharma ##. ##.

  • Blood Disease
  • Pathology
  • Pharmaceutical
  • Therapy
  • FibroGen, Inc.
  • FIBROGEN INC, PHARMACEUTICALS & HEALTHCARE DEALS BY TYPE, 2012 TO YTD 2018
  • FIBROGEN INC, PHARMACEUTICALS & HEALTHCARE, DEALS BY REGION, 2012 TO YTD 2018

Summary FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics.The company’s pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal...

  • Blood Disease
  • Pharmaceutical
  • China
  • United States
  • FibroGen, Inc.

REFERENCE CODE: SMDB## PUBLISHED: APRIL 2016 Social Media Advertising Spend in China, 2016 Databook List of Figures List of Tables ##.

  • Advertising
  • Computer
  • Pharmaceutical
  • Social Network
  • Tencent Holdings Ltd

Brands pay for space on one or more of the online company' s pages to display a static or linked banner or logo.

  • Advertising
  • Computer
  • Online Advertising
  • Pharmaceutical
  • Tencent Holdings Ltd

REFERENCE CODE: SMDB## PUBLISHED: APRIL 2015 Social Media Advertising Spend in China, 2015 Databook List of Figures List of Tables ##.

  • Advertising
  • Marketing
  • Pharmaceutical
  • Social Network
  • Tencent Holdings Ltd

Digital Advertising Spend in China, 2015 Databook REFERENCE CODE: DSDB## PUBLISHED: APRIL 2015 LIST OF FIGURES LIST OF TABLES ##.

  • Advertising
  • Computer
  • Online Advertising
  • Pharmaceutical
  • Tencent Holdings Ltd
  • LARGE MOLECULES COMPETITIVE LANDSCAPE
  • UPDATES

ASP-## Phase II VAP-## inhibitor Astellas Pharma ASP## is orally administered VAP-## inhibitor for treatment of diabetic nephropathy and diabetic macular oedema.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • Angion Biomedica Corp.
  • FibroGen, Inc.
  • and its partners Astellas Pharma Inc. and AstraZeneca in both dialysis-dependent patients and nondialysis-dependent patients.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..1), H2 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018 Summary According to the recently published report ’Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2018’; Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible...

  • Pharmaceutical
  • Japan
  • World
  • Product Initiative
  • FibroGen, Inc.
  • FIBROGEN INC, PHARMACEUTICALS & HEALTHCARE, DEALS BY TYPE, 2012 TO YTD 2018
  • FIBROGEN INC, PHARMACEUTICALS & HEALTHCARE, DEALS BY TYPE, 2012 TO YTD 2018

FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The...

  • Pharmaceutical
  • Therapy
  • United States
  • Company Financials
  • FibroGen, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..1), H1 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

Sigmoid Pharma Ltd.

  • Pharmaceutical
  • China
  • Japan
  • Product Initiative
  • FibroGen, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016 (CONTD..1)

Procter & Gamble Pharmaceuticals, Inc.

  • Blood Disease
  • Hospital
  • Pharmaceutical
  • Therapy
  • FibroGen, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2015 (CONTD...1)
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2015

Both studies will include a ##:## randomization and an open label, active-control, non-inferiority design.

  • Blood Disease
  • Pharmaceutical
  • United States
  • Company Operations
  • FibroGen, Inc.